Caricamento...
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
TAS-115 is a novel MET, VEGFR, FMS and PDGFR inhibitor, developed to improve the continuity of drug administration with a relatively short half-life. We assessed its tolerability, safety, pharmacokinetics, efficacy, and pharmacodynamics in patients with solid tumors. This open-label, dose-escalation...
Salvato in:
| Pubblicato in: | Invest New Drugs |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer US
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7340670/ https://ncbi.nlm.nih.gov/pubmed/31820255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00859-4 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|